|
The Pharmacology Research Associate (PRAT) Program
|
Training Initiative
|
FDA
|
NIGMS
|
Funding provided for the support of a Pharmacology Research Associate (PRAT) Program Associate as a second year fellow in the laboratory at the U.S. Food and Drug Administration.
|
|
The Science of Sex and Gender in Human Health
|
Training Initiative
|
FDA
|
OD/DPCPSI/ORWH
|
This is a Web-based course that offers a basic scientific understanding of the major physiological differences between the sexes; their influence on illness and health outcomes; and their implications for policy, medical research, and health care.
|
|
The Trans-NIH Rare Diseases Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCATS, CC, CSR, FIC, NCCAM, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NLM
|
The Trans-NIH Rare Diseases Working Group was established in 2004. This Working Group assists the Office of Rare Diseases Research in carrying out its mission by addressing a set of goals that build on partnerships the Office of Rare Diseases Research has developed with National Institutes of Health (NIH) Institutes, Centers, and Offices, U.S. Department of Health and Human Services Agencies, and other organizations that address issues in rare diseases research such as identifying research opportunities and advances in rare diseases research; promoting coordination and cooperation in joint research efforts among the NIH Institutes, Centers and Offices and the research entities they support.
|
|
The United Nations 57th Session of the Commission on the Status of Women (CSW)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC
|
NIDA
|
The U.S. Department of Health and Human Services (HHS) Office of Global Affairs–International Health Action for a Healthier U.S. is the lead office for HHS efforts. This office invited representatives from several HHS agencies to prepare for representing HHS at the Commission on the Status of Women meeting in March 2013.
|
|
The United States Renal Data System (USRDS)
|
Resource Development
|
CMS, HRSA
|
NIDDK
|
The United States Renal Data System (USRDS) is a national data system that collects, analyzes, and distributes information about chronic kidney disease and end-stage renal disease (ESRD) in the U.S. The missions of the USRDS are: (1) To characterize the total renal patient population and describe the distribution of patients by socio-demographic variables across treatment modalities; (2) To report on the incidence, prevalence, mortality rates, and trends over time of renal disease by primary diagnosis, treatment modality and other variables; (3) To develop and analyze data on the effect of various modalities of treatment by disease and patient group categories; (4) To identify problems and opportunities for more focused special studies of renal research issues; (5) To conduct cost effectiveness studies and other economic studies of ESRD; and (6) To make the data available to investigators, and by supporting investigator-initiated projects, to conduct biomedical and economic analyses of ESRD patients.
|
|
Therapeutics for Rare and Neglected Diseases (TRND)/FDA Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCATS, CC, NHGRI, NHLBI, NICHD, NINDS
|
A group of Therapeutics for Rare and Neglected Diseases (TRND) staff and U.S. Food and Drug Administration (FDA) staff from the Center for Drug Evaluation and Research (CDER) meet on a semi-monthly basis to discuss projects for the TRND program. The purpose of this working group is to discuss the scientific progress on each project toward the eventual goal of an Investigational New Drug Application for each project. Results of experiments are discussed, and TRND staff takes the feedback of FDA/CDER staff into consideration when developing future project plans.
|
|
Tobacco and Nicotine Research Interest Group (TANRIG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, SAMHSA
|
NIDA, NCI, NHGRI, NHLBI, NIAAA, NIAID, NICHD, NIEHS, NIMH, NINR, OD/DPCPSI/OBSSR
|
The Tobacco and Nicotine Research Interest Group (TANRIG) was formed in January 2003 with the goal of increasing collaboration, coordination, and communication of tobacco- and nicotine-related research among National Institutes of Health Institutes and Centers, as well as with other relevant U.S. Department of Health and Human Services agencies.
|
|
Tobacco Regulatory Science Program (TRSP)
|
Research Initiative
|
FDA
|
OD/DPCPSI/ODP, NCI, OD/OER
|
Located in the National Institutes of Health (NIH) Office of Disease Prevention, the Tobacco Regulatory Science Program (TRSP) coordinates the trans-NIH collaborative effort with the U.S. Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) to conduct research to support its regulatory activities over tobacco products. Within the framework of the Tobacco Control Act, the NIH and FDA formed an interagency partnership to foster tobacco regulatory research. The NIH has the infrastructure for the solicitation, review, and management of research. The FDA has expertise in tobacco regulatory science and the authority and resources to support research responsive to FDA’s regulatory authority. Support from FDA was used to fund grants and to provide administrative support and oversight to manage Funding Opportunity Announcements (FOA), application review, policy implementation and oversight, and communicating and reporting to a variety of sources.
|
|
Toxicology in the 21st Century (Tox21) Program
|
Research Initiative
|
FDA
|
NCATS, NIEHS
|
The Toxicology in the 21st Century (Tox21) initiative, championed by the National Center for Advancing Translational Sciences (NCATS), the National Institute of Environmental Health Sciences (NIEHS), the U.S. Environmental Protection Agency (EPA), and the U.S. Food and Drug Administration (FDA), was formed to develop high-throughput screening tests that measure cellular harm caused by environmental chemicals. The goals of the Tox21 initiative are to identify patterns of compound-induced biological response in order to characterize toxicity and disease pathways, facilitate cross-species extrapolation, and model low dose extrapolation, to prioritize compounds for more extensive toxicological evaluation, and finally, to develop predictive models for biological response in humans.
|
|
Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
NIAID
|
The presidential declaration issued at the 2009 EU-US summit called for the creation of “a transatlantic task force on urgent antimicrobial resistance issues focused on appropriate therapeutic use of antimicrobial drugs in the medical and veterinary communities, prevention of both healthcare- and community-associated drug-resistant infections, and strategies for improving the pipeline of new antimicrobial drugs, which could be better addressed by intensified cooperation between us”. The objectives of the Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) are to increase the mutual understanding of U.S. and EU activities and programs relevant to the antimicrobial resistance issues identified in the declaration to deepen the transatlantic dialogue, provide opportunities to learn from each other, and promote information exchange, coordination and co-operation.
|